Journal: HemaSphere

Article Title: NOTCH1 fusions in pediatric T‐cell lymphoblastic lymphoma: A high‐risk subgroup with CCL17 (TARC) levels as diagnostic biomarker

doi: 10.1002/hem3.117

Figure Lengend Snippet: CCL17 (TARC) in NOTCH1 ‐rearranged patients. (A) CCL17 levels in pg/mL per patient, showing highly elevated CCL17 in blood of NOTCH1 ‐rearranged T‐LBL patients but none of the other patients. 10,000 pg/mL is the maximum measurable CCL17 level with used assay. Orange line in (A–C) represents maximum normal CCL17 level (1300 pg/mL) based on what has been described in Hodgkin lymphoma. ⁹ Patients that had a relapse are indicated with an asterisk. Patient TLBL049 developed a therapy‐related acute myeloid leukemia (double asterisk). (B) For three NOTCH1 ‐rearranged patients, blood CCL17 levels could be determined for a time point of remission after diagnosis, revealing normalized CCL17 levels in all three cases. (C) For four NOTCH1 ‐rearranged patients blood CCL17 levels were determined at time point of relapse and remission after relapse (second remission), revealing increased levels in three relapses that again normalized in second remission. (D) Staining for TARC using anti‐CCL17 antibody for four NOTCH1 ‐rearranged patients showing that T‐LBL cells do not express high levels of CCL17 based on immunohistochemistry.

Article Snippet: Immunohistochemistry staining for CCL17 was performed on the BOND‐III fully automated staining system (Leica) using CCL17 rabbit polyclonal antibody (ProteinTech Group).

Techniques: Biomarker Discovery, Staining, Immunohistochemistry

Journal: Nature Communications

Article Title: Single-cell transcriptomics analysis of bullous pemphigoid unveils immune-stromal crosstalk in type 2 inflammatory disease

doi: 10.1038/s41467-024-50283-3

Figure Lengend Snippet: a Hierarchical plot showing inferred intercellular communication network of CCL17 - CCR4 signaling. b The feature plot and the bar chart showing CCL17 mRNA expression within total skin cells between BP ( n = 5) and HC ( n = 8). c Protein level of CCL17 in serum from BP ( n = 73) and HC ( n = 32) by ELISA. d The feature plot and the bar chart showing CCR4 mRNA expression within total skin cells between BP ( n = 5) and HC ( n = 8). In the box plot b – d : Minima: Lower limit of the whisker. Maxima: Upper limit of the whisker. Center: Median line inside the box. The upper and lower box bounds represent the 25% and 75% percentile of data. e Flow plots of CD3 + T cells from PBMCs showing the expression of CCR4 treated by CCL17 recombinant protein (left panel), and the frequency of CCR4 (right panel) in BP ( n = 30) and HC ( n = 16) groups. f The positive correlation between the level of PLA2G2A and CCL17 in serum from in BP patients ( n = 73). P -value was calculated using two-sided Pearson correlation test. r -value was Pearson correlation coefficient. g The level of CCL17 in PBMC from BP patients ( n = 26) and HC ( n = 7) treated with PLA2G2A recombinant protein. h Effect of CCL17 treatment on the IL-13 secretion from BP patients ( n = 26) and HC ( n = 13). i Effect of PLA2G2A treatment on the IL-13 secretion from BP patients ( n = 20) and HC ( n = 13). j , k ELISA analysis of anti-BP180-NC16A antibody titers in supernatants of CCL17 ( j ) or PLA2G2A ( k ) stimulated PBMCs from BP patients ( n = 26) and HC ( n = 22). P -values in b–d were calculated using two-sided Mann–Whitney U-test. P -values in e and g – k were calculated using paired two-sided Student’s t -test. * P < 0.05, ** P < 0.01, **** P < 0.0001, only P -values < 0.05 are shown. Each sample is represented as one dot.

Article Snippet: The serum levels of IL-13 (EK0424), IL-4 (EK0404), IL-5 (EK0407), PLA2G2A (EK1944), and CCL17 (EK0684) in both patients and controls were quantified using ELISA Development Kits from BosterBio, USA, following the manufacturer’s instructions.

Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Whisker Assay, Recombinant, MANN-WHITNEY

Journal: Nature Communications

Article Title: Single-cell transcriptomics analysis of bullous pemphigoid unveils immune-stromal crosstalk in type 2 inflammatory disease

doi: 10.1038/s41467-024-50283-3

Figure Lengend Snippet: It illustrates a positive feedback loop where fibroblasts respond to Th2 cells through the IL13RA1 - IL13 pair, leading to increased secretion of PLA2G2A and CXCL12. This, in turn, amplifies the Th2-mediated response. (i) The lesional fibroblasts respond to IL-13 and induce the overexpression of PLA2G2A, which promotes the expression of CXCR4 on the surface of immune cells to recruit the immune cells from peripheral blood into skin lesions. (ii) Fibroblasts-derived PLA2G2A and myeloid cells-derived CCL17 elevate the secretion of IL-13, and fibroblast and myeloid cells further respond to IL-13, forming a positive feedback loop between immune cells and fibroblasts. (iii) IL-13 activates B cells to secrete autoantibodies. (iv) In blister, the secretion of autoantibodies recruits T cells, myeloid cells, mast cells, neutrophils and eosinophils. T cell-derived IL-13 activates eosinophils to secrete various cytokines (including IL-13), which further promotes Th2 polarization and mediates the crosstalk between immune cells.

Article Snippet: The serum levels of IL-13 (EK0424), IL-4 (EK0404), IL-5 (EK0407), PLA2G2A (EK1944), and CCL17 (EK0684) in both patients and controls were quantified using ELISA Development Kits from BosterBio, USA, following the manufacturer’s instructions.

Techniques: Over Expression, Expressing, Derivative Assay